High flow nasal cannula in acute hypercapnic exacerbation of chronic obstructive pulmonary disease: an emerging utility

Anshul Mittal1, Megha Varshney2, Vidushi Rathi1, Pranav Ish1

1Department of Pulmonary, Critical Care And Sleep Medicine, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi; 2Department of Medicine, Vardhman Mahavir Medical College And Safdarjung Hospital, New Delhi, India

Abstract

High flow nasal cannula (HFNC) provides warmed and humidified air with flow rates up to 60 liters/min with relatively fixed oxygen content (FiO2). It has been extensively evaluated for hypoxemic respiratory failure and has been used in mild acute respiratory distress syndrome, pre-intubation, bronchoscopy and pediatric obstructive sleep apnea. Recent data has suggested a role in stable hypercapnic chronic obstructive pulmonary disease (COPD) and even in acute exacerbations, though, the use has not been advocated by any guidelines yet. We present a case of acute hypercapnic exacerbation of COPD, intolerant to non-invasive ventilation, showing response and improvement on use of HFNC. This case highlights this potential mechanisms and prospects for the same.

Introduction

Although non-invasive positive-pressure ventilation (NIV) is the therapy of choice for acute hypercapnic respiratory failure in chronic obstructive pulmonary disease (COPD), some patients are intolerant to its use. High flow nasal cannula (HFNC) supportive therapy has emerged as a safe, useful therapy in patients with respiratory failure, improving oxygenation and comfort. We hereby report a case of hypercapnic respiratory failure with intolerance for use of NIV where HFNC use was successful.

Case Report

A 75-year lady, current smoker and diagnosed COPD, on irregular inhaled dual bronchodilators for 10 years, was admitted with complaints of progressively worsening dyspnoea following fever for two days and increased cough with expectoration, both in amount and purulence. The patient had no co-morbidities like diabetes, hypertension or coronary artery disease.

On general examination, the patient was conscious but agitated, with a pulse rate of 90/min, respiratory rate of 28/min and blood pressure of 118/82 mmHg. On systemic examination, bilateral rhonchi were heard in lung fields, with rest of examination being within normal limits. Presenting arterial blood gas revealed respiratory acidosis as summarized in Table 1 along with other laboratory parameters. The patient had neutrophilic leukocytosis with preserved organ functions.

On echocardiography, her right atrium and ventricle were dilated and left ventricle ejection fraction (LVEF) was 65% with pulmonary artery pressures of 30 mmHg. Chest x-Ray was suggestive of bilateral emphysematous lung field with flattening of diaphragm (Figure 1). On lung ultrasound no B lines or C pattern was appreciated and there was no evidence of effusion. Patient was uncooperative for use of NIV with oro-nasal mask and consent for invasive mechanical ventilation was denied by kin.

Hence, high flow oxygen through nasal cannula at a flow rate of 30-35L/min and FiO2 of around 30% (to target saturation of 88-92%) was used along with parenteral antibiotic, oral steroids and nebulization with bronchodilators (levalbuterol and ipratropium) (Figures 2 and 3). The patient’s vital and consciousness status were monitored at regular interval of one hour and arterial blood gas was repeated at 4, 8 and 12 h (Table 1). Patient clinical condition improved gradually, and her arterial blood gas normalized after 12 h with resolution of respiratory acidosis with patient becoming alert and oriented. The respiratory rate also decreased
from 28 to 18/min. She was discharged on day 6 post admission with advice of home oxygen and inhaled bronchodilators. The leukocytosis had resolved as well as fever. She was asked to follow up after 2 weeks for further therapy optimization, rehabilitation, and plan for long term oxygen therapy.

**Discussion**

HFNC has many uses (Table 2). The above described case presents as an uncommon occasion were HFNC was used to manage a case of acute hypercapnic respiratory failure in a COPD successfully. In patient with acute hypercapnic respiratory failure, NIV has been the primary modality to improve tidal volume and maintain alveolar ventilation hence improving oxygenation and resolving hypercapnia. But around 25% of patients have contraindication for use of NIV and another 15% tolerate it poorly due to mask intolerance, claustrophobia and development of pressure sore or dryness of throat [1]. In such patients HFNC can be used as an alternate mode of ventilation to prevent intubation.
and provide them ventilator support. The device uses an oxygen air blender with an actively heated humidifying device which can provide FiO₂ from 21 to 60% at a flow rate of as high as 60 l/min [2].

HFNC cannot actively enhance tidal volume, it mainly functions in hypercapnic failure by flushing the pharyngeal dead space and improving alveolar ventilation. HFNC also improves thoraco-abdominal synchrony, thereby decreasing respiratory rate. Hence, eventually the minute ventilation falls without reducing alveolar ventilation and PCO₂ is reduced. Another suggested mechanism is that although delivered through open system, high flow overcomes resistance against expiratory flow and creates positive nasopharyngeal pressure which helps to recruit lung and decrease the work of breathing [3].

The use of humidified air increases mucociliary function to provide effective clearing of airway and associated with less atelectasis which improves ventilation perfusion matching providing better oxygenation at a lower FiO₂. These are particularly important in patients of COPD which have secretions and are at risk of oxygen toxicity at higher FiO₂ [4]. All these mechanisms have been summarized in Table 3. Evidence in hypoxic respiratory failure is robust but no official guidelines exist for the same yet [5-7]. There are studies showing a potential benefit of HFNC in stable COPD but use in acute COPD is recent [9,10]. A recent study of over 50 stable hypercapnic COPD also indicated a favorable response in terms of rapid shallow breathing index (RSBI) and even PCO₂ levels. This implored for further studies in acute hypercapnic COPD patients [10]. The GOLD 2019 guidelines also mention regarding the role of HFNC in COPD in hypoxic respiratory failure. They have no mention for use of HFNC in hypercapnic respiratory failure due to acute exacerbation.

An observational retrospective cohort study in acute hypercapnic COPD patients presenting to emergency care comparing NIV and HFNC found comparable failure rates with evidence of decreased skin breakdown complications and nursing care requirements in HFNC patients. In fact, the duration of HFNC use was superior to NIV with a high tolerance rates, and most common cause of NIV failure was intolerance. However, again, the study had a retrospective cohort with a small sample size and itself warrants need for well-designed randomized control trials [11]. A single randomized trial in China has demonstrated that HFNC decreases diaphragmatic fatigue in acute exacerbation of COPD without much difference in arterial blood analysis [12]. Another randomized control trial of over 200 patients comparing HFNC and NIV in undifferentiated emergency setting respiratory failure also conclusively showed that HFNC is non-inferior. The subgroup of patients which had hypercapnia at presentation (30%) also had similar ventilatory improvements in PCO₂ levels. Patients could easily communicate and feed, decreasing anxiety levels, thereby increasing the practical utility [13].

Hence, to conclude HFNC can be used as an alternative mode of ventilation in COPD patients presenting as acute exacerbation with contraindication or intolerance to use of NIV. But still further research needs to be done regarding timing the start, monitoring and end point of therapy for patient in whom its use is warranted.

Table 3. Mechanisms responsible for HFNC success in acute hypercapnic respiratory failure of COPD (adapted from references 10-13).

<table>
<thead>
<tr>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>1  High flow washing out dead space</td>
</tr>
<tr>
<td>2  Improved thoraco-abdominal synchrony improving alveolar ventilation</td>
</tr>
<tr>
<td>3  No claustrophobia</td>
</tr>
<tr>
<td>4  High flow creating a small PEEP effect and recruitment</td>
</tr>
<tr>
<td>5  Humidified and moist air to improve comfort and manage secretions</td>
</tr>
<tr>
<td>6  Fixed FiO₂ preventing oxygen toxicity</td>
</tr>
</tbody>
</table>

HFNC, high flow nasal cannula; COPD, chronic obstructive pulmonary disease; PEEP, positive end-expiratory pressure; FiO₂, fraction of inspired oxygen.
References